Abstract: A customizable holder for vials and test tubes is described herein. The holder includes a body having an inclined portion and a vertical portion joined together. A guide is present in the inclined portion for accepting elastic clamps for holding a vial or test tube. The elastic clamps have a slot and aperture therein to retain a vial or test tube.

Abstract: A smart package backing (100) for pills removable from the backing, wherein the backing is adapted to record a removal of said pills by means of detection elements (103, 401a, 501a). The detection elements comprise electrical components (401a, 501a), wherein said electrical components are pressed onto the backing (100) with methods of printing technology. The removal of a pill from the backing is adapted to bring about a structural change in at least one printed component, and the structural change of said component is adapted to bring about an electrically measurable change in an electric circuit comprising said component. In addition, at least one of said electrical components (401a, 501a) deviates in terms of its specific electrical value from the specific electrical value of at least one other electrical component (401a, 501a).

Abstract: A liquid cleansing composition comprising water in an amount sufficient to form a liquid composition, a fatty acid soap, a structuring agent, and talc. The cleansing composition has a creamy texture and provides good skinfeel properties.

Abstract: Gel-wipes suitable for use in personal care and household cleansing applications are disclosed, which include a substrate having a first surface, a second surface opposing the first surface and a body disposed between and defined by the first and second surfaces, fibers having an outer surface and an inner core, a polymeric gel distributed throughout the substrate such that a substantial portion of the fibers contain the polymeric gel distributed throughout the inner core of the fibers; and a liquid cleansing composition, wherein the inner core of a substantial portion of the fibers and the polymeric gel are substantially free of the liquid cleansing composition; as well as methods of making the gel-wipe.

Abstract: Compositions and methods are disclosed for preventing or reducing frizzy appearance of keratin fibers, including hair, and reducing the amount of fly-away strands of hair, particularly in humid conditions, by forming a coating on hair that is resistant to water vapors from the air or surrounding environment. The compositions comprise a combination of a hydrophobic particulate material comprising a hydrophobically surface-modified oxide and one or more hydrophobic film formers in a cosmetically acceptable vehicle.

Abstract: The present invention relates to a composition in the form of an emulsion containing portions of hollow spheres of organosilicon-based material, the portions of hollow spheres having a mean diameter ranging from 0.05 to 10 ?m. The invention also relates to physiologically acceptable emulsion compositions comprising hollow spheres, and to a process for fading out skin surface defects, in particular to reduce the sheen of the skin and/or to fade out pores, shadows under the eyes, marks, wrinkles and/or fine lines, comprising the topical application to the skin of the above-mentioned compositions.

Abstract: The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.

Abstract: Present invention relates to a process for manufacturing emulsion composition which comprises an oil phase dispersed in a continuous water phase which is stabilized with a surfactant as an emulsifier. The present invention is on a method for producing an emulsion comprising one or more fatty alcohol, one or more oil liquid at 20° C. and one or more surfactant wherein one or more surfactant is added to the dispersion of one or more fatty alcohol and one or more oil liquid at 20° C. in water at a temperature of 50° C. or higher, preferably 60° C. or higher with the condition that the temperature of the dispersion is at least 10° C. higher than the melting point of fatty alcohol having the highest melting point, more preferably between 60 and 85° C. wherein the emulsion thus obtained does not comprise dispersed droplets with a volume size larger than or equal to 10 ?m measured directly without dilution of the emulsion at 20° C. measured with a laser particle size analyzer suitable therefore.

Abstract: A formulation for personal hygiene in the form of O/W emulsion with a pH from 5.5 to 6.5, free of surfactants, comprising an emulsifier consisting of a fatty alcohol from 14 to 22 carbon atoms or of Glyceryl Stearate or a mixture thereof, Coco Caprylate and/or Coco Caprylate/Caprate, vitamin E or an ester thereof, and Melaleuca alternifolia oil.

Abstract: Compositions containing an effective dermatological disease-treating or dermatological condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle are disclosed.

Abstract: A personal care composition exhibiting a tan delta of about 0.30 or more at about 10° C. includes a primary surfactant, secondary surfactant, and a polyol. Methods are also provided to improve the stability of a personal care composition.

Abstract: Provided are an internal olefin sulfonate composition which is capable of sufficiently enhancing foamability, light foam quality, and instantaneous foam dissipation property, and a cleansing composition containing the internal olefin sulfonate composition. The internal olefin sulfonate composition comprises (A) an internal olefin sulfonate having 12 carbon atoms and (B) an internal olefin sulfonate having 14 carbon atoms, wherein a content mass ratio of the component (A) to the component (B), (A/B), is from 10/90 to 90/10, and a total content of the component (A) and the component (B) in the internal olefin sulfonate is from 60 to 100% by mass.

Abstract: The present invention relates to the cosmetic use of one or more catalytic oxidation compounds chosen from porphyrins, phthalocyanines and/or porphyrazines as deodorant agent. The present invention also relates to a cosmetic treatment method comprising the application, to a surface of a keratinous substance, of a cosmetic composition comprising, in a cosmetically acceptable medium, one or more catalytic oxidation porphyrin, phthalocyanine and/or porphyrazine compounds.

Abstract: The invention relates to a cosmetic composition, in particular a composition for making up and/or caring for keratin materials, preferably a nail makeup, comprising the compound of chemical formula (I) below: (I) in which: m represents an integer equal to 0 or 1; n represents an integer between 2 and 8; R1 represents a group (C1-C20)alkyl or an aryl group, or alternatively, when m is equal to 0, R1 may also represent a carbonyl; R2 and R3 represent an ethoxy group or a group (C1-C20)alkyl, optionally substituted with an amino group; Y represents a polyurea or a polyurethane or alternatively a hydrocarbon-based group comprising from 2 to 100 carbon atoms. The invention also relates to a cosmetic process, in particular a makeup or hair shaping process, preferably a process for making up keratin materials, in particular the nails and/or the hair, characterized in that it comprises at least one step which consists in applying a cosmetic composition as above defined to keratin materials.

Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.

Abstract: Described herein are oral care compositions comprising an effective amount of an enzyme cocktail, wherein the enzyme cocktail comprises an alkaline protease and a second enzyme selected from cellulose, ?-glucanase, and combinations thereof, in an orally acceptable carrier, together with methods of making and using the same.

Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

Abstract: The present invention relates to a cosmetic composition comprising a latex film forming polymer, a hyperbranched functional polymer, an organic solvent and water. The compositions of the present invention may optionally contain at least one colorant. The invention also relates to a method for making up and/or enhancing the appearance of a keratinous substrate, in particular lashes, by applying these compositions to the keratinous substrate.

Abstract: The invention relates to water-soluble or water-swellable polymers the repeating structural units of which consist of a) 90.0 to 99.99 mole-% of one or more repeating structural units originating from special monomers with sulfonic acid groups or the salts thereof such as for example 2-acrylamido-2-methyl-propanesulfonic acid or the salts thereof and b) 0.01 to 10.0 mole-% of one or more repeating structural units originating from special cross-linking agents with at least three polymerizable double bonds. The polymers for example have an advantageous sensory property profile and are highly suitable as thickening agents even in salt-containing compositions. They are furthermore advantageously suitable for producing cosmetic, dermatological or pharmaceutical compositions.

Abstract: A hair cosmetic composition comprising the following components (A) and (B) and having a pH of 6 or less: (A) an oxyalkylene polymer represented by the following general formula (a1): -(AO)n— (a1) wherein A represents an alkylene group having 2 to 6 carbon atoms and n represents a number from 50 to 30,000, provided that n number of AOs consist of at least two alkyleneoxy groups and are arranged through either random polymerization or block polymerization; and (B) a polymer containing a component unit represented by the following general formula (b1) and a component unit represented by the following general formula (b2) in a mass ratio (b1)/(b2) of 50/50 to 100/0: —(CH2CR1COOH)— (b1) —(CH2CR2COOR3)— (b2) wherein R1 and R2 represent H or CH3 and R3 represents a C2-20 hydrocarbon group.

Abstract: The present invention provides a water-soluble polyalkylene oxide-modified product which is nonionic, has a high thickening effect and is also excellent in transparency, and an emulsion composition and a cosmetic material containing the same. More specifically, the present invention provides a water-soluble polyalkylene oxide-modified product obtained by reacting a monovalent hydrophobic alcohol, a linear diol compound, a polyalkylene oxide compound and a diisocyanate compound, and an emulsion composition and a cosmetic material containing the same.

Abstract: This invention relates to a dual phase mouthwash comprising a hydrophilic phase, a hydrophobic phase, and a hydrotrope, wherein the hydrophilic phase comprises an effective amount of a preservative selected from methylisothiazolinone, sodium benzoate, potassium sorbate, and combinations thereof, as well as to methods of using and of making such compositions.

Abstract: A method for stimulating hair growth includes providing a topical composition including a purified oil extract from Melaleuca alternifolia, also known as tea tree. The method may further include applying the topical composition to the skin surrounding the follicles of the human hair at least once a day. A method for preventing the loss of human hair includes providing a topical composition including a purified oil extract from Melaleuca alternifolia, also known as tea tree. The method may further include applying the topical composition to the skin surrounding the follicles of the human hair at least once a day.

Abstract: The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in normal, aged and damaged dermal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the skin mediated by cyclooxygenase (COX) and lipoxygenase (LOX).

Abstract: Disclosed is a method of treating fine lines or wrinkles, the method comprising topically applying to skin in need thereof a composition comprising topically applying to skin in need thereof a composition comprising Magnolia officinalis bark extract, Vitis vinifera seed extract, tocopherol or tocopherol acetate, and lecithin or dextrin.

Abstract: A gastroretentive composition comprises a mixture comprising an active ingredient component and an excipient component. The excipient component comprises a first water-soluble reaction product produced from a precursor comprising a vinyl group, and a copolymer of a polyalkylene glycol and a second water-soluble reaction product produced from a precursor comprising a vinyl group. A method of forming the gastroretentive composition comprises the steps of providing the active ingredient component and the excipient component, and mixing the active ingredient component and the excipient component to form a mixture. The mixture is aggregated to form an aggregation that is dry granulated to form a plurality of granules. The plurality of granules is processed to form the gastroretentive composition.

Abstract: Disclosed are highly stable compositions having outstanding storage stability and/or demonstrating exceptional resistance to aqueous solution degradation, the composition including an orally active nucleotide analog or an orally active nucleotide analog prodrug, which is orally bioavailable, such as adefovir dipivoxil and tenofovir disoproxil. For example, when a composition of the invention is stored for 1 month or for 18 months at 25° C. and 60% relative humidity, its orally active nucleotide analog or orally active nucleotide analog prodrug degrades to provide a composition containing no more than 0.2% or no more than 0.7% by weight of a less orally bioavailable impurity, respectively. Also disclosed are a container/closure package system including the composition and a package insert and methods of manufacturing the composition and treating a patient for a disease or condition, for example, a viral disease or cancer, with the use of the composition.

Abstract: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.

Abstract: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent.

Abstract: The present invention is to providing a new preparation including complex of a medical compound with lutein, astaxanthin and antioxidant. The new preparation includes stabilized liposome preparation, sustained release preparation and polymeric micelles preparation which used as delivery systems for lutein, astaxanthin and antioxidant. The new preparation significantly increases bioavailability of lutein and astaxanthin and uses for treatment and prevention of eyes and other disease.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterized in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.

Abstract: A block copolymer comprising ?-caprolactone units and polyoxyethylene stearate units, wherein the block copolymer has the following formula: wherein n, m, and p are integers greater than 0. The block copolymer is prepared by polymerizing (i) ?-caprolactone and (ii) polyoxyethylene stearate in the presence of a catalyst such as stannous octoate.

Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.

Abstract: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins. e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly (amino acid) as the active ingredient, e.g. a peptide or protein, shows a rapid disintegration and/or dissolution such that the active ingredient is able to attain a therapeutic effect.

Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.

Abstract: Controlled release dosage forms comprising a pharmaceutically active agent capable of not more than 90% release in 12 hours in a simulated gastric juice in first order release rate USP type 1 dissolution test, comprising (a) a tablet made from polymer matrix of at least two biocompatible polymers, the pharmaceutically active agent and excipients; the tablet capable of rapid swelling without disintegration in simulated gastric juice to a size resulting in gastric retention in the stomach and controlled release of the active agent by controlled erosion and diffusion immediately after coming into contact with the gastric juice, or (b) microspheres of ungrafted chitosan or a chitosan derivative or CARBOPOL® incorporating the active agent which is not a polymeric molecule and after administration in stomach, the microspheres adhere to the gastric mucosa for a long and controlled time release of the active agent.

Abstract: The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet.

Abstract: The invention provides controlled release oral dosage formulations containing one or more active agents, and methods of using same. In one aspect, the formulation is in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. The core may contain one or more enteric materials or polymeric materials which modulates the release of the active agent.

Abstract: Embodiments of liquid-filled hard gel capsule pharmaceutical formulations comprise a non-emulsified mixture, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight medium chain triglycerides, and about 5 to about 25% by weight medium chain mono/diglycerides, wherein the medium chain triglycerides and medium chain mono/diglycerides are present at a ratio by weight of from about 10:1 to about 5:1.

Abstract: A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.

Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Abstract: A method of preparing naringenin nanoparticles comprises dissolving naringenin in an organic solvent to form a solution; adding the solution to boiling water under ultrasonic conditions to form a mixture; and stirring the mixture to obtain the naringenin nanoparticles. The organic solvent can be at least one of methanol, ethanol, dichloromethane and chloroform. Ultrasonic conditions can include applying ultrasonic energy at a frequency of 30-60 kHz and a power of 100 watts for about 20-30 minutes to the mixture.

Abstract: The present invention provides a patch or patch preparation in which the anchoring property of a pressure-sensitive adhesive layer to a support is improved with no adverse effects on its pressure-sensitive adhesive properties such as adhesion, pressure-sensitive adhesiveness, and a cohesive strength. A support of the present invention is for a patch or patches preparation, and comprises a base material containing a plastic film and an undercoat agent layer laminated on the base material. The undercoat layer contains porous inorganic particles having an average particle diameter of from 1 ?m to 15 ?m. A patch and patch preparation of the present invention comprises the support and a pressure-sensitive adhesive layer placed on one surface of the support to be adjacent to the undercoat agent layer.

Abstract: Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.

Abstract: The present invention relates to a synergistic pharmaceutical composition comprising Compound C2 (Neo-isopulegol), C3 (Iso-pulegol) and C4 (Citronellol) derived from herbal seed extract of Litsea cubeba useful for the treatment of lung cancer. The present invention also relates to the activity of compounds C2 or C3 or C4 either alone or in combination in killing of A549 lung cancer cells.

Abstract: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.

Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.

Abstract: Disclosed is a method for inhibiting cancer cell growth in a subject in need thereof, comprising administering to the subject an effective amount of a compound from Antrodia camphorata, wherein the compound is represented by formula (I): wherein R1 is a hydrogen atom or an acetyl group; and a method of inhibiting cancer cell growth by using the compound, the cancer is selected from the group consisting of lung cancer, colon cancer, prostate cancer, liver cancer and breast cancer.

Abstract: The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.